Development of potent and selective inhibitors of ecto-5′- nucleotidase based on an anthraquinone scaffold

Younis Baqi, Sang Yong Lee, Jamshed Iqbal, Peter Ripphausen, Anne Lehr, Anja B. Scheiff, Herbert Zimmennann, Jürgen Bajorath, Christa E. Müller

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

ecto-5′-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels. eN inhibitors have potential as novel drugs, for example, for the treatment of cancer. In the present study, we synthesized and investigated a series of 55 anthraquinone derivatives as potential inhibitors of eN, 11 of which are novel compounds and another 11 of which had previously been described but have now been synthesized by an improved method. We identified several potent inhibitors of rat eN. The most potent compounds were l-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2- sulfonate (45, PSB-0952, K1 = 260 nM) and 1-amino-4-[2- anthracenylamino]-9,10-dioxo-9,10dihydroanthracene-2-sulfonate (52, PSB-0963, 150 nM), with 52 being the most potent eN inhibitor described to date. Selected compounds were further characterized and found to exhibit a competitive mechanism of inhibition. Investigations of ecio-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compound 45 exhibited the highest degree of selectivity ( > 150-fold).

Original languageEnglish
Pages (from-to)2076-2086
Number of pages11
JournalJournal of Medicinal Chemistry
Volume53
Issue number5
DOIs
Publication statusPublished - Mar 11 2010

Fingerprint

Purinergic P2Y2 Receptors
Anthraquinones
5'-Nucleotidase
Nucleosides
Adenosine
Pharmaceutical Preparations
Neoplasms
triphosphoric acid

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Development of potent and selective inhibitors of ecto-5′- nucleotidase based on an anthraquinone scaffold. / Baqi, Younis; Lee, Sang Yong; Iqbal, Jamshed; Ripphausen, Peter; Lehr, Anne; Scheiff, Anja B.; Zimmennann, Herbert; Bajorath, Jürgen; Müller, Christa E.

In: Journal of Medicinal Chemistry, Vol. 53, No. 5, 11.03.2010, p. 2076-2086.

Research output: Contribution to journalArticle

Baqi, Y, Lee, SY, Iqbal, J, Ripphausen, P, Lehr, A, Scheiff, AB, Zimmennann, H, Bajorath, J & Müller, CE 2010, 'Development of potent and selective inhibitors of ecto-5′- nucleotidase based on an anthraquinone scaffold', Journal of Medicinal Chemistry, vol. 53, no. 5, pp. 2076-2086. https://doi.org/10.1021/jm901851t
Baqi, Younis ; Lee, Sang Yong ; Iqbal, Jamshed ; Ripphausen, Peter ; Lehr, Anne ; Scheiff, Anja B. ; Zimmennann, Herbert ; Bajorath, Jürgen ; Müller, Christa E. / Development of potent and selective inhibitors of ecto-5′- nucleotidase based on an anthraquinone scaffold. In: Journal of Medicinal Chemistry. 2010 ; Vol. 53, No. 5. pp. 2076-2086.
@article{ba74484ae7a24ce48f6d8c52aedea582,
title = "Development of potent and selective inhibitors of ecto-5′- nucleotidase based on an anthraquinone scaffold",
abstract = "ecto-5′-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels. eN inhibitors have potential as novel drugs, for example, for the treatment of cancer. In the present study, we synthesized and investigated a series of 55 anthraquinone derivatives as potential inhibitors of eN, 11 of which are novel compounds and another 11 of which had previously been described but have now been synthesized by an improved method. We identified several potent inhibitors of rat eN. The most potent compounds were l-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2- sulfonate (45, PSB-0952, K1 = 260 nM) and 1-amino-4-[2- anthracenylamino]-9,10-dioxo-9,10dihydroanthracene-2-sulfonate (52, PSB-0963, 150 nM), with 52 being the most potent eN inhibitor described to date. Selected compounds were further characterized and found to exhibit a competitive mechanism of inhibition. Investigations of ecio-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compound 45 exhibited the highest degree of selectivity ( > 150-fold).",
author = "Younis Baqi and Lee, {Sang Yong} and Jamshed Iqbal and Peter Ripphausen and Anne Lehr and Scheiff, {Anja B.} and Herbert Zimmennann and J{\"u}rgen Bajorath and M{\"u}ller, {Christa E.}",
year = "2010",
month = "3",
day = "11",
doi = "10.1021/jm901851t",
language = "English",
volume = "53",
pages = "2076--2086",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Development of potent and selective inhibitors of ecto-5′- nucleotidase based on an anthraquinone scaffold

AU - Baqi, Younis

AU - Lee, Sang Yong

AU - Iqbal, Jamshed

AU - Ripphausen, Peter

AU - Lehr, Anne

AU - Scheiff, Anja B.

AU - Zimmennann, Herbert

AU - Bajorath, Jürgen

AU - Müller, Christa E.

PY - 2010/3/11

Y1 - 2010/3/11

N2 - ecto-5′-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels. eN inhibitors have potential as novel drugs, for example, for the treatment of cancer. In the present study, we synthesized and investigated a series of 55 anthraquinone derivatives as potential inhibitors of eN, 11 of which are novel compounds and another 11 of which had previously been described but have now been synthesized by an improved method. We identified several potent inhibitors of rat eN. The most potent compounds were l-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2- sulfonate (45, PSB-0952, K1 = 260 nM) and 1-amino-4-[2- anthracenylamino]-9,10-dioxo-9,10dihydroanthracene-2-sulfonate (52, PSB-0963, 150 nM), with 52 being the most potent eN inhibitor described to date. Selected compounds were further characterized and found to exhibit a competitive mechanism of inhibition. Investigations of ecio-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compound 45 exhibited the highest degree of selectivity ( > 150-fold).

AB - ecto-5′-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels. eN inhibitors have potential as novel drugs, for example, for the treatment of cancer. In the present study, we synthesized and investigated a series of 55 anthraquinone derivatives as potential inhibitors of eN, 11 of which are novel compounds and another 11 of which had previously been described but have now been synthesized by an improved method. We identified several potent inhibitors of rat eN. The most potent compounds were l-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2- sulfonate (45, PSB-0952, K1 = 260 nM) and 1-amino-4-[2- anthracenylamino]-9,10-dioxo-9,10dihydroanthracene-2-sulfonate (52, PSB-0963, 150 nM), with 52 being the most potent eN inhibitor described to date. Selected compounds were further characterized and found to exhibit a competitive mechanism of inhibition. Investigations of ecio-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compound 45 exhibited the highest degree of selectivity ( > 150-fold).

UR - http://www.scopus.com/inward/record.url?scp=77949418623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949418623&partnerID=8YFLogxK

U2 - 10.1021/jm901851t

DO - 10.1021/jm901851t

M3 - Article

VL - 53

SP - 2076

EP - 2086

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -